Metabolomics Market Report and Forecast 2025-2034

The global metabolomics market was valued at USD 2.50 Billion in 2024, driven by the rising prevalence of chronic diseases across the globe. The market is anticipated to grow at a CAGR of 12.36% during the forecast period of 2025-2034 to achieve a value of USD 8.02 Billion by 2034.

Metabolomics Market Overview

Metabolomics can be defined as a branch of science that deals with the analysis of metabolites in organisms to establish information on functioning cells as well as diseases. Biomarker discovery, drug development, toxicology, and determining the nutritional value of foods are some of the fields where it is commonly used. Metabolites are accurately quantified and identified by mass spectrometry, nuclear magnetic resonance spectroscopy, chromatography, or other techniques that are frequently used in the clinical and research fields.

Metabolomics Market Growth Drivers

Pharmaceutical and Biotechnology Research Boost the Market Growth

There is a growing application of metabolomics in the pharmaceutical and biotechnology industries to optimize drug discovery and development. It offers knowledge of drug actions, potency, and toxicity to enhance the drug pipeline. Scientists employ this technique to confirm drug targets, determine the effects of a particular drug on the candidate metabolism, and estimate its pharmacokinetics and toxicity. This information enhances the formulation process, lowers the occurrence of failures towards the end, and increases the probability of bringing new therapies and treatments on the market.

Increasing Prevalence of Chronic Disease to Foster Demand for Metabolomics Market

Globally, the prevalence of cancer, diabetes, and cardiovascular diseases, among others, has increased over time, demanding better diagnostic and treatment tools, including metabolomics.

For instance, the Centers for Disease Control and Prevention (CDC) reports that diabetes impacts 38.4 million individuals. Among them, 29.7 million have received a diagnosis, while 8.7 million cases remain undetected. These diseases are common causes of morbidity and mortality globally, thus necessitating better and more accurate diagnostic, assessment, and management procedures.

Metabolomics Market Trends

Integration of Multi-Omics

The combination of metabolomic profiling with other forms of omics is helping researchers gain a better understanding of the biological system, thus providing better diagnostic tools for diseases and therapeutic interventions. It is believed that this trend will further improve the importance and utilization of metabolomics in research and clinical practice.

Collaboration and Partnerships

Research collaborations between universities, industries, and research institutions are boosting the advancement of metabolomics. These associations are promoting the utilization and advancement of metabolomics in various fields.

Technological Advancements

Advanced technologies and equipment, coupled with improved data processing tools, are making metabolomics studies faster and more precise. These advancements are expected to make metabolomics more affordable and widely adopted in drug discovery, clinical diagnostics, and other areas.

Growing Use in Drug Discovery and Development

Metabolomics is rising to prominence in the realm of drug discovery and development in terms of target identification, drug action clarification, as well as the determination of drug output and risk profiles. Metabolite profiling helps researchers comprehend the pathways that differ in disease conditions, enhance the effectiveness of drugs, and discover the signs of toxicity. Oncology is among the areas that benefit from this approach since it helps identify the metabolic characteristics that may be linked to drug resistance and the subsequent creation of combination therapies.

Recent Developments in the Metabolomics Market

In September 2023, the National Institutes of Health (NIH) research grants allocated USD 50.3 million to the Multi-Omics for Health and Disease Consortium to support further multi-omics work in human health and disease. The consortium is expected to launch strategic approaches to clinical research with populations of ancestry as a source of complexity in its first year with USD 11 million worth funding. This project, in turn, funded by NHGRI, NCI, and NIEHS, involved processing samples at an omics production center and making data available to the scientific community to enhance the understanding of a particular disease and design treatments and new drugs.

In June 2023, Waters Corporation improved and expanded the SELECT SERIES™ MRT System, enhancing its specificity to extensively serve metabolomics, UPLC-MS/MS, and MSI specs in drug discovery. Modifications include 50% higher resolution, 300,000 FWHM resolution, a scan rate that is now three times faster, and mass value accuracy in parts per billion. The new REM gives scientists the ability to differentiate between analytes in biological fluid and tissue samples, improving the efficiency of metabolomics and MS imaging.

Metabolomics Market Segmentation

The report titled “Global Metabolomics Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Product and Services

• Metabolomics Instruments
• Separation Tools
• Detection Tools
• Metabolomics Bioinformatics Tools and Services

Market Breakup by Application

• Biomarker Discovery
• Drug Discovery
• Toxicology Testing
• Nutrigenomics
• Functional Genomics
• Personalized Medicine
• Other Applications

Market Breakup by Indication

• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Inborn Errors of Metabolism
• Other Indications

Market Breakup by End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Metabolomics Market Share

Market Segmentation Based on Indication to Witness Substantial Growth

Based on the indication, the market is segmented into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. Among these, the use of metabolomics in cancer diagnosis and treatment is expected to gain more traction as it can provide early and accurate diagnostic capabilities, as well as individualized therapies for patients. Metabolomics yields real-time metabolic signatures that have been correlated with the precise changes that manifest in various types of cancer at different stages. This enables the detection of the disease at an early stage, providing patients with a unique therapeutic management plan that improves treatment results and reduces side effects.

Metabolomics Bioinformatics Tools and Services Anticipated to Have Largest Market Share Based on Product and Services

Based on the product and services, the market is divided into metabolomics instruments, and metabolomics bioinformatics tools and services. Metabolomic instruments are further divided into separation and detection tools. Among these, metabolomics bioinformatics tools and services are expected to lead the market share due to the large amount of data obtained in metabolomics studies. These tools are crucial for analysing and discovering trends from large amounts of data. As metabolomics broadens its applications to other sectors, its requirements will also increase to help researchers access significant data.

Metabolomics Market Analysis by Region

Based on the region, the market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Of these regions, North America is expected to dominate, owing to its developed healthcare system, high spending on healthcare, and pioneering investments in modern, advanced medical technologies.

Europe is a large market for metabolomics, particularly Germany, the United Kingdom, and France. Government support is highly favorable in the region, healthcare infrastructure is well developed, and recently, a trend toward more individualized treatments have emerged.

Leading Players in the Metabolomics Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:

Agilent Technologies, Inc.

The company was established in 1999 and is based in California, USA. It provides high-performing mass spectrometers such as the Agilent 6545XT AdvanceBio LC/Q-TOF for metabolite identification and quantification.

Thermo Fisher Scientific, Inc.

This Massachusetts, USA-based company was established in 1956. Its product range is primarily focused on high-resolution mass spectrometry, which features the Thermo Scientific Q Exactive and Orbitrap series.

Bruker Corporation

Founded in 1960 and headquartered in Massachusetts, USA. The company provides the latest mass spectrometry tools such as the Bruker timsTOF PRO and maXis II for ultra-high-resolution analysis.

Other companies include Shimadzu Corporation, Bio-Rad Laboratories Inc., Metabolon, Inc., Danaher Corporation, PerkinElmer Inc., Human Metabolome Technologies, and Bioanalytical Systems, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been in the report.

Key Questions Answered in the Metabolomics Market

• What was the global metabolomics market value in 2024?
• What is the global metabolomics market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What are the major factors aiding the global metabolomics market demand?
• What are the market's major drivers, opportunities, and restraints?
• Which regional market is expected to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• What are the major global metabolomics market trends?
• How does the rise in the geriatric population impact the market size?
• Who are the key players involved in the metabolomics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
• What is the market segmentation based on the product and services?
• What are the latest advancements in metabolomics instruments?
• What role do bioinformatics tools play in metabolomics analysis?
• What is the market breakup based on the mode of application?
• How is metabolomics transforming the drug discovery process?
• What are the emerging applications of metabolomics in functional genomics?
• What is the market segmentation based on the indication?
• What are the latest trends in metabolomics research for cancer?
• What are the potential metabolomic biomarkers for cardiovascular diseases?
• What is the market segmentation based on the end user?
• What are the benefits of metabolomics for drug development in pharmaceutical companies?
• What is the market breakup based on the region?
• How is the regulatory landscape in North America affecting the metabolomics market?

This product will be delivered within 3-5 business days.